The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
Figure 3
Effect of enzastaurin on BrdU incorporation.
UM cells were treated with enzastaurin at indicated concentrations for 40 h and then labeled with BrdU for additional 6–8 hours. BrdU incorporation was presented as % of untreated control. Mean ± SD of 3 independent experiments are shown. * P<0.05, versus control; # P<0.01, versus control. WT = GNAQ wild type; MT = GNAQ mutation.